Yatharth Hospitals Q4 FY26: Profit Up, Margin Slips

Stock drops after Q4 FY26 numbers

Shares of Yatharth Hospital & Trauma Care Services Ltd (NSE: YATHARTH, BSE: 543950) fell sharply in Monday’s afternoon trade after the company reported its March 2026 quarter (Q4 FY26) results. The stock slid as much as 7.18% to an intraday low of Rs 801 even as the hospital chain reported strong year-on-year growth in revenue and profit. At another point during the session, the stock was reported down 4.51% at Rs 824 on the BSE. Separately, the stock was also tracked at Rs 829.80, down 3.84% versus the previous close of Rs 862.95. The day’s trading range was reported at Rs 889.80 on the high side and Rs 827.40 on the low side. The immediate market reaction appeared linked to margin pressure during the quarter.

What the company reported for Q4 FY26

Yatharth Hospitals reported a 47% increase in revenue from operations to Rs 341.5 crore in Q4 FY26 compared with Q4 FY25. Consolidated net profit for the quarter rose 23% year-on-year to Rs 47.5 crore. The company’s EBITDA stood at Rs 79.9 crore, up 37% from Rs 58.3 crore in the same quarter last year. Alongside the operational growth, the company also disclosed that Group ARPOB (average revenue per occupied bed) increased 5% year-on-year to Rs 33,283. The ARPOB increase was attributed to a higher contribution from high-value specialties and traction across newer hospitals.

Margin contraction becomes the focus

Despite higher revenue and EBITDA, the reported EBITDA margin declined. The EBITDA margin reduced by 161 basis points (bps) year-on-year to 23.4% in Q4 FY26, versus 25% in Q4 FY25. This margin contraction was a key point investors appeared to track, given it arrived in a quarter where revenue and profit grew strongly. The company also disclosed that the EBITDA margin adjusted for ramp-up losses stood at 30.4% during the quarter. That adjusted figure indicates that expansion and integration-related losses at newer assets can materially affect reported profitability.

Another set of profit figures cited in market reports

One set of market commentary also cited profit after tax (PAT) rising 15% year-on-year to Rs 44.7 crore from Rs 38.7 crore in the corresponding quarter last year. The same report noted EBITDA advanced 37% year-on-year and 6% quarter-on-quarter, while the margin contracted by 161 bps year-on-year to 23.4%. These figures broadly align on the direction of performance (higher profit and EBITDA, lower margin), although the PAT number differs from the consolidated net profit figure of Rs 47.5 crore reported elsewhere. Investors typically focus on the consistency between growth and margin performance, especially during periods of hospital capacity ramp-up.

Management commentary: acquisitions, integration, and NCR expansion

Yatharth Tyagi, Whole Time Director, said the company saw a strong close to FY26, describing Q4 as an “industry-leading performance”. He highlighted the group’s ability to acquire newer hospitals and integrate and scale them towards profitability. Management pointed to newer hospitals at Model Town (New Delhi), Faridabad Sector-20, and Agra as having scaled up rapidly and contributed to group revenues within a short span. The company also said integration of the Agra facility strengthened its regional presence. Separately, management referenced entry into Gurugram with a 250-bed “ultra-modern, high-end” hospital, positioning it within the NCR market.

What the price action said on the day

The stock’s decline was notable because it came despite record year-on-year revenue growth being highlighted in market coverage. In the same session, peers showed mixed moves, based on the figures cited: Max Healthcare Institute was down 2.15%, Apollo Hospitals Enterprise was up 0.55%, and Narayana Hrudayalaya was up 4.69%. The combination of a sharp intraday fall and a margin contraction suggests traders were weighing near-term profitability and operating leverage rather than only top-line momentum. For healthcare services, margins can be sensitive to case mix, ramp-up costs, staffing, and the pace at which newer facilities reach utilisation targets.

Snapshot table: key figures cited for Q4 FY26

Analyst coverage and shareholding detail cited

Market data cited in the provided information showed 0 analysts with a “strong buy” rating and 2 analysts with a “buy” rating, with 0 analysts giving a “sell” rating. The same information also stated promoter holding remained unchanged at 55.80% in the March 2026 quarter. While analyst counts can vary by source and coverage universe, the figures indicate limited published coverage at the time of reporting. For smaller hospital chains, the number of active covering analysts is often lower than for larger listed peers.

Market impact: why margins matter alongside growth

The immediate market impact was visible in the stock’s sharp fall even after revenue and profit growth. In hospital businesses, investors often track EBITDA margin as a proxy for operating efficiency, pricing power, and the ability to convert higher occupancy and case mix into cash generation. A decline of 161 bps year-on-year to 23.4% can be interpreted as pressure from ramp-up losses, cost increases, or mix changes, depending on what the company discloses and how the quarter compares with previous periods. The company’s disclosure of a 30.4% margin adjusted for ramp-up losses provides context that new facilities can dilute reported margins in the short run.

Analysis: balancing expansion with profitability

The management commentary emphasised acquisitions, integration, and rapid scale-up across newer hospitals, alongside entry into Gurugram with a 250-bed facility. That strategy can expand the revenue base quickly, but it can also raise operating costs before utilisation stabilises, particularly at new locations. The quarter’s data points show that revenue and EBITDA rose strongly year-on-year, while reported margins declined, consistent with a growth phase where fixed-cost absorption is still improving. Investors are likely to keep tracking how quickly newer hospitals move from ramp-up to steady-state performance, and whether the gap between reported margin (23.4%) and adjusted margin (30.4%) narrows over time.

Conclusion

Yatharth Hospitals delivered strong Q4 FY26 growth in revenue, EBITDA, and profit, but the stock fell as investors reacted to a year-on-year margin contraction. The company has framed the margin movement in the context of ramp-up losses and ongoing integration of newer hospitals. In the near term, the market will likely watch for follow-through on scaling newer facilities and any updates on operating efficiency as the group expands further in NCR, including Gurugram.